These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9506009)

  • 1. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men.
    Yu Z; Gupta SK; Hwang SS; Kipnes MS; Mooradian AD; Snyder PJ; Atkinson LE
    J Clin Pharmacol; 1997 Dec; 37(12):1139-45. PubMed ID: 9506009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application.
    Yu Z; Gupta SK; Hwang SS; Cook DM; Duckett MJ; Atkinson LE
    J Clin Pharmacol; 1997 Dec; 37(12):1129-38. PubMed ID: 9506008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose.
    Brocks DR; Meikle AW; Boike SC; Mazer NA; Zariffa N; Audet PR; Jorkasky DK
    J Clin Pharmacol; 1996 Aug; 36(8):732-9. PubMed ID: 8877678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men.
    Singh AB; Norris K; Modi N; Sinha-Hikim I; Shen R; Davidson T; Bhasin S
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2437-45. PubMed ID: 11397836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
    Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
    Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA
    J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
    Meikle AW; Matthias D; Hoffman AR
    BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men.
    Raynaud JP; Aumonier C; Gualano V; Betea D; Beckers A
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):177-84. PubMed ID: 18325758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
    Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men.
    Wilson DE; Meikle AW; Boike SC; Fairless AJ; Etheredge RC; Jorkasky DK
    J Clin Pharmacol; 1998 Jan; 38(1):54-9. PubMed ID: 9597560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
    Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal testosterone delivery in castrated Yucatan minipigs: pharmacokinetics and metabolism.
    Xing QF; Lin S; Chien YW
    J Control Release; 1998 Mar; 52(1-2):89-98. PubMed ID: 9685939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males.
    Korbonits M; Slawik M; Cullen D; Ross RJ; Stalla G; Schneider H; Reincke M; Bouloux PM; Grossman AB
    J Clin Endocrinol Metab; 2004 May; 89(5):2039-43. PubMed ID: 15126518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
    Winters SJ; Atkinson L
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
    Wang C; Swerdloff R; Kipnes M; Matsumoto AM; Dobs AS; Cunningham G; Katznelson L; Weber TJ; Friedman TC; Snyder P; Levine HL
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3821-9. PubMed ID: 15292312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.